Encore

Articles, interviews and presentations on nonclinical drug development — toxicology, antibody–drug conjugates and the path from candidate to IND.

In drug development I look for the story

On nonclinical safety, the line between tolerable and intolerable toxicity, ADCs, CAR-T and AI as a tool for toxicologists.